DD272851A5 - Verfahren zum herstellen von 2-(1-pentyl-3-guanidino)-4-(2-methyl-4-imidazolyl)thiazol-dihydrochlorid-trihydrat - Google Patents
Verfahren zum herstellen von 2-(1-pentyl-3-guanidino)-4-(2-methyl-4-imidazolyl)thiazol-dihydrochlorid-trihydrat Download PDFInfo
- Publication number
- DD272851A5 DD272851A5 DD87318777A DD31877787A DD272851A5 DD 272851 A5 DD272851 A5 DD 272851A5 DD 87318777 A DD87318777 A DD 87318777A DD 31877787 A DD31877787 A DD 31877787A DD 272851 A5 DD272851 A5 DD 272851A5
- Authority
- DD
- German Democratic Republic
- Prior art keywords
- methyl
- guanidino
- imidazolyl
- pentyl
- trihydrate
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title abstract description 4
- 238000000034 method Methods 0.000 claims abstract description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- 239000003960 organic solvent Substances 0.000 claims description 2
- 239000011260 aqueous acid Substances 0.000 claims 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 16
- 239000000047 product Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 10
- 150000003839 salts Chemical class 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000002253 acid Substances 0.000 description 8
- 150000001412 amines Chemical group 0.000 description 7
- 150000004684 trihydrates Chemical class 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000002775 capsule Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- DBODNPMIIRVQGW-UHFFFAOYSA-N trihydrate;dihydrochloride Chemical compound O.O.O.Cl.Cl DBODNPMIIRVQGW-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 239000012442 inert solvent Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- DPBLXKKOBLCELK-UHFFFAOYSA-N pentan-1-amine Chemical compound CCCCCN DPBLXKKOBLCELK-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- IXBPPZBJIFNGJJ-UHFFFAOYSA-N sodium;cyanoiminomethylideneazanide Chemical compound [Na+].N#C[N-]C#N IXBPPZBJIFNGJJ-UHFFFAOYSA-N 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- UNFYYORNCSLJEW-UHFFFAOYSA-N 1,3-thiazole trihydrate dihydrochloride Chemical compound O.O.O.Cl.Cl.S1C=NC=C1 UNFYYORNCSLJEW-UHFFFAOYSA-N 0.000 description 1
- GIMNAEMRNXUAQP-UHFFFAOYSA-N 2-[4-(2-methyl-1h-imidazol-5-yl)-1,3-thiazol-2-yl]guanidine Chemical compound N1C(C)=NC=C1C1=CSC(N=C(N)N)=N1 GIMNAEMRNXUAQP-UHFFFAOYSA-N 0.000 description 1
- BJEGCKZYQRBQMG-UHFFFAOYSA-N 2-[4-(2-methyl-1h-imidazol-5-yl)-1,3-thiazol-2-yl]guanidine;dihydrochloride Chemical compound Cl.Cl.N1C(C)=NC(C=2N=C(NC(N)=N)SC=2)=C1 BJEGCKZYQRBQMG-UHFFFAOYSA-N 0.000 description 1
- -1 2-methyl-4-imidazolyl Chemical group 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 150000003842 bromide salts Chemical class 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 229940100684 pentylamine Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C335/00—Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C335/04—Derivatives of thiourea
- C07C335/24—Derivatives of thiourea containing any of the groups, X being a hetero atom, Y being any atom
- C07C335/28—Y being a hetero atom, e.g. thiobiuret
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US1986/002307 WO1988003140A1 (en) | 1986-10-29 | 1986-10-29 | Crystalline 2-(1-pentyl-3-guanidino)-4-(2-methyl-4-imidazolyl)thiazole dihydrochloride trihydrate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DD272851A5 true DD272851A5 (de) | 1989-10-25 |
Family
ID=22195693
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD87318777A DD272851A5 (de) | 1986-10-29 | 1987-10-27 | Verfahren zum herstellen von 2-(1-pentyl-3-guanidino)-4-(2-methyl-4-imidazolyl)thiazol-dihydrochlorid-trihydrat |
| DD87308315A DD262659A5 (de) | 1986-10-29 | 1987-10-27 | Verfahren zum herstellen von 2-(1-pentyl-3-guanidino)-4-(2-methyl-4-imidazolyl)thiazol und seines kristallinen dihydrochlorid-trihydrats |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DD87308315A DD262659A5 (de) | 1986-10-29 | 1987-10-27 | Verfahren zum herstellen von 2-(1-pentyl-3-guanidino)-4-(2-methyl-4-imidazolyl)thiazol und seines kristallinen dihydrochlorid-trihydrats |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4997949A (cs) |
| JP (1) | JPS63122680A (cs) |
| AU (1) | AU579775B2 (cs) |
| CA (1) | CA1313378C (cs) |
| DD (2) | DD272851A5 (cs) |
| FI (1) | FI89918C (cs) |
| NO (1) | NO170417C (cs) |
| PH (1) | PH23922A (cs) |
| RU (1) | RU1779252C (cs) |
| WO (1) | WO1988003140A1 (cs) |
| ZA (1) | ZA878083B (cs) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5387597A (en) * | 1991-02-25 | 1995-02-07 | Pfizer Inc. | Hemiphosphate hemihydrate of 2-(1-pentyl-3-guanidino)-4-(2-methyl-4-imidazolyl)thiazole |
| NO329085B1 (no) * | 2008-01-31 | 2010-08-16 | Sorbwater Technology As | Fremgangsmate og apparat for separasjon av fluidfaser, samt anvendelser derav |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN163170B (cs) * | 1980-10-14 | 1988-08-20 | Pfizer | |
| US4560690A (en) * | 1984-04-30 | 1985-12-24 | Pfizer Inc. | 2-(N-substituted guanidino)-4-hetero-arylthiazole antiulcer agents |
| US4632993A (en) * | 1984-10-11 | 1986-12-30 | Pfizer Inc. | Process for making 2-guanidino-4-(2-methyl-4-imidazolyl) thiazole dihydrobromide |
| JPS6191122A (ja) * | 1984-10-11 | 1986-05-09 | フアイザー・インコーポレーテツド | ２―グアニジノ―４―（２―メチル―４―イミダゾリル）チアゾール類からなる慢性関節リウマチ治療用組成物 |
-
1986
- 1986-10-29 WO PCT/US1986/002307 patent/WO1988003140A1/en active IP Right Grant
- 1986-10-29 US US07/365,155 patent/US4997949A/en not_active Expired - Lifetime
-
1987
- 1987-10-27 DD DD87318777A patent/DD272851A5/de not_active IP Right Cessation
- 1987-10-27 DD DD87308315A patent/DD262659A5/de not_active IP Right Cessation
- 1987-10-27 CA CA000550298A patent/CA1313378C/en not_active Expired - Fee Related
- 1987-10-27 PH PH35990A patent/PH23922A/en unknown
- 1987-10-28 AU AU80428/87A patent/AU579775B2/en not_active Ceased
- 1987-10-28 ZA ZA878083A patent/ZA878083B/xx unknown
- 1987-10-29 JP JP62274631A patent/JPS63122680A/ja active Granted
-
1988
- 1988-06-28 NO NO88882861A patent/NO170417C/no unknown
-
1989
- 1989-04-24 RU SU894613898A patent/RU1779252C/ru active
- 1989-04-28 FI FI892034A patent/FI89918C/fi not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NO882861L (no) | 1988-06-28 |
| NO882861D0 (no) | 1988-06-28 |
| FI892034L (fi) | 1989-04-28 |
| AU8042887A (en) | 1988-05-05 |
| DD262659A5 (de) | 1988-12-07 |
| NO170417B (no) | 1992-07-06 |
| PH23922A (en) | 1990-01-23 |
| NO170417C (no) | 1992-10-14 |
| JPS63122680A (ja) | 1988-05-26 |
| WO1988003140A1 (en) | 1988-05-05 |
| FI89918B (fi) | 1993-08-31 |
| US4997949A (en) | 1991-03-05 |
| AU579775B2 (en) | 1988-12-08 |
| CA1313378C (en) | 1993-02-02 |
| FI892034A0 (fi) | 1989-04-28 |
| RU1779252C (ru) | 1992-11-30 |
| ZA878083B (en) | 1989-06-28 |
| FI89918C (fi) | 1993-12-10 |
| JPH0513952B2 (cs) | 1993-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69318077T2 (de) | Triazolylthiomethylthiocephalosporin-Hydrochlorid, sein kristallines Hydrat und seine Herstellung | |
| CH637130A5 (de) | Chinazolin-derivate, verfahren zu ihrer herstellung und verwendung dieser derivate in arzneimitteln. | |
| DE2847621A1 (de) | Phthalazin-derivate, verfahren zu ihrer herstellung und solche derivate enthaltende arzneimittel | |
| DE2614669C2 (de) | Gamma-kristalline wasserfreie Form von 7-(D-alpha-Formyloxy-alpha-phenylacetamido)-3-(1-methyl-1H-tetrazol-5- ylthiomethyl)-3-cephem-4-natriumcarboxylat und Verfahren zu ihrer Herstellung | |
| DE2524321A1 (de) | Antibakterielle verbindungen,verfahren zu ihrer herstellung und sie enthaltende arzneimittel | |
| DD272851A5 (de) | Verfahren zum herstellen von 2-(1-pentyl-3-guanidino)-4-(2-methyl-4-imidazolyl)thiazol-dihydrochlorid-trihydrat | |
| DE3750023T2 (de) | Verfahren zur Herstellung von 2-(1-Pentyl-3-guanidino)-4-(2-methyl-4-imidazolyl)Thiazol und dessen kristallinisches Dihydrochlorid-Trihydrat. | |
| DD261163A5 (de) | Verfahren zur reinigung von cephalosporin-antibiotika | |
| DE60312953T2 (de) | Stabiles lansoprazol, enthaltend mehr als 500 ppm bis zu 3000 ppm wasser und mehr als 200 ppm bis zu 5000 ppm alkohol | |
| DE2128941A1 (de) | Neue Derivate des 2 Amino 5 Chlor Thiazols | |
| DE2127734A1 (de) | Neue Nitrofuranderivate und Verfahren zu ihrer Herstellung | |
| DE2655130C3 (de) | Eine praktisch lösungsmittelfreie Kristallform des Cefacetril-Natriumsalzes | |
| DE102005020104A1 (de) | Neue Thiazolidinone ohne basischen Stickstoff, deren Herstellung und Verwendung als Arzneimittel | |
| DE2252323C3 (de) | 3,6-Dialkyl-23-dihydro-2,9-dioxo-6H,9H-thiazolo [5,4-fj chinolin-e-carbonyl- Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Bakterizide | |
| DE2011885C3 (de) | 1,4-Dihydro-3-carboxy-cyclopentano (h)-chinolon-(4)-derivate, Verfahren zur Herstellung derselben und ihre Verwendung | |
| DD238234A5 (de) | Verfahren zur herstellung von 2-guanidino-4-(1-methyl-4-imidazolyl)thiazol | |
| CH615442A5 (en) | Process for the preparation of 17alpha,21-diesters of 17alpha,21-dihydroxysteroids of the pregnane series | |
| DE2043817C3 (de) | 1,4-Dihydro-3-carboxy-cyclopentano-(h)-chinolon-(4)-derivate, Verfahren zu deren Herstellung sowie deren Verwendung zur Bekämpfung antibakterieller Erkrankungen | |
| CH460016A (de) | Verfahren zur Herstellung neuer Nitrothiazolverbindungen | |
| DD293808A5 (de) | Verfahren zur herstellung von (5-[bis(2-chlorethyl)amino]-1-methyl-benzimidazolyl(2)ethansaeurealkylestern | |
| CH460017A (de) | Verfahren zur Herstellung neuer Nitrothiazolverbindungen | |
| DE1670539C3 (de) | Diacylthiamine und Verfahren zu deren Herstellung | |
| DE2617198C2 (de) | 6-n-Propoxybenzthiazol-2-methylcarbamat, Verfahren zu seiner Herstellung und es enthaltende Arzneimittel | |
| DE1770402C3 (de) | N-Methyl-N-naphthyl-(1)-dithiocaTbamtnsäwre-2-benzoxazoVytester, Arzneimittel und Verfahren zu seiner Herstellung | |
| AT249672B (de) | Verfahren zur Herstellung von neuen Imidazolderivaten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ENJ | Ceased due to non-payment of renewal fee |